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Background:  Approximately 50% of patients presenting with clinical features of heart failure have a preserved ejection fraction (HFPEF). 
The key pathophysiologic basis for the HFPEF is impaired diastolic reserve, with abnormally elevated filling pressures at rest or during 
physical activity. We report the midterm results of a novel inter-atrial shunt device (IASD) intended to lower left atrial pressure by creating a 
small permanent inter-atrial communication.
Aims and methods:  Eleven patients were enrolled under an approved protocol in a prospective multicenter feasibility study. Key inclusion 
criteria were: EF > 45%; PCWP at rest ≥ 15 or exercise ≥ 25mm Hg; ≥ 1 hospitalization for heart failure within prior 12 months, or persistent 
NYHA Class III/IV for at least 3 months.
results:  (Table) Mean pt. age was 70±12 years and most patients had ≥2 co-morbidities (mean 2.6). The IASD was successfully placed 
in each patient and remained patent at final follow-up. Two SAEs occurred within 30 days, and both resolved. IASD placement was 
associated with significant improvements in quality of life together with reduced HF hospitalization (HFH). At one year, all patients were 
alive and the composite rate of survival, freedom from HFH and freedom from worsening quality of life was 73%.
conclusion:  This initial data shows that the shunt device can be safely implanted and that meaningful midterm clinical improvement can 
be obtained in patients with heart failure and preserved or mildly reduced ejection fraction.
Parameter Baseline 12 Months p value
LVEF (%) 58±7 55±13 ns
NYHA (III/IV) 82/18 45/0 0.017
6 Min Walk Dist (m) 315±152 343±76 ns
MLWHF Score 53±17 37±17 0.057
HFH (no./10 pt years) 1.36 0.73 0.033
